Following ASCO 2023, experts in oncology review recent data updates from KEYNOTE-789 on chemotherapy with or without pembrolizumab for TKI-resistant nonsquamous NSCLC.
Rahul Gosain, MD
Advertisement
Articles by Rahul Gosain, MD
Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
4
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
5